Clinical Trial Update: Intranasal Insulin for COVID-19-related Smell Loss [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intranasal insulin for COVID-19-related smell loss has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anosmia
• Hyposmia
• Paraosmia
• Smell Loss

Drugs mentioned

• Intranasal insulin (insulin)

Snippet

Sponsor: Universidad Panamericana | Conditions: Anosmia, Smell Loss | Phase 3 | Status: COMPLETED